Compare STT & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | STT | WAT |
|---|---|---|
| Founded | 1792 | 1958 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Laboratory Analytical Instruments |
| Sector | Finance | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 45.0B | 42.2B |
| IPO Year | 2021 | 1996 |
| Metric | STT | WAT |
|---|---|---|
| Price | $174.29 | $473.89 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 24 |
| Target Price | $192.63 | ★ $503.29 |
| AVG Volume (30 Days) | ★ 1.8M | 905.6K |
| Earning Date | 10-14-2026 | 11-03-2026 |
| Dividend Yield | ★ 2.14% | N/A |
| EPS Growth | ★ 14.49 | N/A |
| EPS | ★ 9.82 | N/A |
| Revenue | ★ $13,944,000,000.00 | N/A |
| Revenue This Year | $14.18 | $105.39 |
| Revenue Next Year | $5.67 | $10.19 |
| P/E Ratio | $17.51 | ★ N/A |
| Revenue Growth | ★ 7.26 | N/A |
| 52 Week Low | $111.63 | $282.77 |
| 52 Week High | $195.93 | $482.28 |
| Indicator | STT | WAT |
|---|---|---|
| Relative Strength Index (RSI) | 54.44 | 59.22 |
| Support Level | $170.05 | $419.81 |
| Resistance Level | $175.46 | $482.28 |
| Average True Range (ATR) | 3.75 | 16.34 |
| MACD | 0.85 | 0.21 |
| Stochastic Oscillator | 86.92 | 71.57 |
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $54 trillion in assets under custody and administration, and $5.7 trillion in assets under management, as of Dec. 31, 2025, State Street operates globally in more than 100 geographic markets and employs about 51,500 worldwide.
Waters sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. In early 2026, Waters merged with Becton Dickinson's life science and diagnostics business, which increased its concentration in diagnostics and discovery-related life science tools.